AVITA Medical EBIT

The latest EBIT for RCEL is $-22M as of June 2026. That compares with $-46M in the prior-year period — up 53.5% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside AVITA Medical's historical trend and sector peers before judging valuation or financial health.

Over the past year, RCEL's EBIT moved from $-46M to $-22M — a 53.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AVITA Medical's operating scale or balance-sheet position.

Against its sector companies, RCEL currently prints $-22M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at AVITA Medical's growth, margins, and balance sheet.

A EBIT figure of $-22M for RCEL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting RCEL's EBIT ($-22M), review year-over-year change from $-46M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.